Clasp Therapeutics, a company that aims to create a next-generation version of immunoncology drugs called bispecific T cell engagers (TCEs), launched today with $150 million in series A financing. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback